Spanish Lung Cancer Group

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

1 in Phase 3

Quick facts

Phase 3 pipeline

Docetaxel/Cisplatin control · Oncology
This combination uses docetaxel (a microtubule-stabilizing taxane) and cisplatin (a platinum-based DNA-damaging agent) to inhibit cell division and induce apoptosis in lung cancer cells.

Phase 2 pipeline

paclitaxel, carboplatin and bevacizumab
Tirosin Kinase Inhibitors

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

Spanish Lung Cancer Group portfolio CI brief
Spanish Lung Cancer Group pipeline updates RSS

Frequently asked questions about Spanish Lung Cancer Group

What is Spanish Lung Cancer Group's pipeline?

Spanish Lung Cancer Group has 1 drugs in Phase 3, 2 in Phase 2, 0 in Phase 1. Late-stage candidates include Docetaxel/Cisplatin control.

Sector hub: All tracked pharma companies